Microscan Celebrates 20 Years of Data Matrix Codes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Microscan Celebrates 20 Years of Data Matrix Codes


Microscan, a manufacturer of precision data acquisition and control solutions for automation and OEM applications, celebrates the 20th anniversary of the two-dimensional (2D) data matrix code. Since the invention of data matrix in 1994 by International Data Matrix, Inc. (I.D. Matrix), 2D data matric codes have played an important role in track and trace in manufacturing and production, which includes pharmaceutical products.

A single data matrix code can hold thousands of characters. Its benefits include the compact size, data-carrying capacity and generous reading tolerance. According to Microscan, data matrix can be read at lower contrast ratios than most barcode symbologies, which is advantageous in environments where codes may be obscured and in cases where the code is directly applied to metal and other reflective surfaces through various marking methods.

Data Matrix codes with scratches, tears, or stains can be successfully read without data loss, even if more than 20% of the symbol is damaged, making it the code of choice in data tracking and traceability regulations and standards, such as the FDA and EU regulations for packaging of pharmaceutical products.  

Source: Microscan

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here